Prospective randomized placebo-controlled study of granulocyte- macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma

Journal of Clinical Oncology

Volumn 15, Issue 2, 1997, Pages 660-666

  Moreau, P ^a   Fiere, D ^a   Bezwoda, W R ^a   Facon, T ^a   Attal, M ^a   Laporte, J P ^a   Colombat, P ^a   Haak, H L ^a   Monconduit, M ^a   Lockhorst, H ^a   Girault, D ^a   Harousseau, J L ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 18844470988     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.2.660     Document Type: Article

References (45)

1. McElwain TJ, Powles RL: High-dose intravenous melphalan for plasma-cell leukemia and myeloma. Lancet 2:822-824, 1983
2. Selby PJ, McElwain TJ, Nandi AC, et al.: Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 66:55-62, 1987
3. Barlogie B, Alexanian R, Smallwood L, et al.: Prognostic factors with high-dose melphalan for refractory myeloma. Blood 72:2015-2019, 1988
4. Lokhorst HM, Meuwissen OJAT, Verdonk LF, et al.: High risk multiple myeloma treated with high dose melphalan. J Clin Oncol 10:47-51, 1992
5. Cunningham D, Paz-Ares L, Gore ME, et al.: High-dose melphalan for multiple myeloma: Long-term follow-up data. J Clin Oncol 12:764-768, 1994
6. Barlogie B, Hall R, Zander A, et al.: High dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 67:1298-1301, 1986
7. Barlogie B, Alexanian R, Dicke K, et al.: High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 70:869-872, 1987
8. Harousseau JL, Milpied N, Laporte JP, et al.: Double-intensive therapy in high-risk multiple myeloma. Blood 79:2827-2833, 1992
9. Cunningham D, Paz-Ares L, Milan S, et al.: High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 12:759-763, 1994
10. Vesole DH, Barlogie B, Jagannath S, et al.: High-dose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants. Blood 84:950-956, 1994
11. Samuels BL, Bitran JD: High-dose intravenous melphalan: A review. J Clin Oncol 13:1786-1799, 1995
12. Barlogie B, Jagannath S, Dixon DO, et al.: High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma. Blood 76:677-680, 1990
13. Jagannath S, Barlogie B, Dicke K, et al.: Autologous bone marrow transplantation in multiple myeloma: Identification of prognostic factors. Blood 76:1860-1866, 1990
14. Attal M, Huguet F, Schlaiffer D, et al.: Intensive combined therapy for previously untreated aggressive multiple myeloma. Blood 79:1130-1136, 1992
15. Fermand JP, Chevret S, Ravaud P, et al.: High dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: Results of a phase II trial involving 63 patients. Blood 82:2005-2009, 1993
16. Harousseau JL, Attal M, Divine M, et al.: Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the French Registry on Autologous Transplantation in Multiple Myeloma. Blood 85:3077-3085, 1995
17. Tricot G, Jagannath S, Vesole D, et al.: Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 85:588-596, 1995
18. Attal M, Harousseau JL, Stoppa AM, et al.: High dose therapy in multiple myeloma: Final analysis of a prospective randomized study of the Intergroupe Français du Myélome (IFM 90). Blood 86:125a, 1995 (suppl 1, abstr)
19. Harousseau JL, Attal M, Divine M, et al.: Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplnatation after first remission induction treatment in multiple myeloma. Bone Marrow Transplant 15:963-969, 1995
20. Barlogie B, Crowley J, Jagannath S, et al.: Superior outcome after early autotransplantation with total therapy compared to standard SWOG treatment for multiple myeloma. Blood 86:207a, 1995 (suppl 1, abstr)
21. Chen BJ, Epstein J: Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells. Blood 87:1972-1976, 1996
22. Berenson J, Wong K, Kim K: Evidence for peripheral B lymphocytic but not T lymphocyte involvement in multiple myeloma. Blood 70:1550-1553, 1987
23. Van Riet, Heirman C, Lacor P, et al.: Detection of monoclonal B lymphocytes in bone marrow and peripheral blood of multiple myeloma patients by immunoglobulin gene rearrangement studies. Br J Haematol 73:289-295, 1989
24. Bird JM, Bloxham D, Samson D, et al.: Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. Br J Haematol 88:110, 1994
25. Billadeau D, Quam L, Thomas W, et al.: Detection and quantification of malignant cells in the peripheral blood of multiple myeloma patients. Blood 80:1818-1824, 1992
26. Vora AJ, Toh CH, Peel J, et al.: Use of granulocyte colony-stimulating factor (G-CSF) for mobilizing peripheral blood stem cells: Risk of mobilizing clonal myeloma cells in patients with bone marrow infiltration. Br J Haematol 86:180-182, 1994
27. Celsing F, Hast R, Stenre L: Extramedullary progression of multiple myeloma following GM-CSF treatment. Ground for caution? Eur J Haematol 49:108, 1992 (letter)
28. + cells to remove circulating tumor cells. Blood 87:1625-1634, 1996
29. Corradini P, Voena C, Astolfi M, et al.: High-dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 85:1596-1602, 1995
30. Witzig TE, Gertz MA, Pineda AA, et al.: Detection of monoclonal plasma cells in the peripheral blood stem cell harvests of patients with multiple myeloma. Br J Haematol 89:640-642, 1995
31. + stem cells do not contain clonal myeloma cells. Blood 86:381-389, 1995
32. Brenner MK, Rill DR, Moen RC, et al.: Gene marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 341:85-86, 1993
33. Deisseroth AB, Zu Z, Claxton D, et al.: Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia contribute to relapse after autologous bone marrow in CML. Blood 83:3068-3076, 1994
34. Reece DE, Barnett MJ, Connors JM, et al.: Treatment of multiple myeloma with intensive chemotherapy followed by autologous bone marrow transplantation using marrow purged with 4 hydroxyperoxycyclosphophamide. Bone Marrow Transplant 11:139, 1993
35. Anderson KC, Andersen J, Soiffer R, et al.: Monoclonal anti-body-purged bone marrow transplantation therapy for multiple myeloma. Blood 82:2568-2576, 1993
36. Gobbi M, Tazzari PL, Cavo M: Autologous bone marrow transplantation with immunotoxin-purged marrow for multiple myeloma. Long-term results in 14 patients with advanced disease, in Pileri A, Boccadoro M (eds): Multiple Myeloma (from biology to therapy). Torino, Italy, 1991, pp 137-139
37. Goldmacher VS, Bourret LA, Levine BA, et al.: Anti-CD38-blocked ricin: An immunotoxin for the treatment of multiple myeloma. Blood 84:3017-3025, 1994
38. + peripheral blood progenitor cell after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 86:390-397, 1995
39. - peripheral blood stem cells effect timely trilineage engrafment in multiple myeloma. Blood 86:293a, 1995 (suppl 1, abstr)
40. Harousseau JL, Facon T, Maloisel T, et al.: GCSF instead of autologous stem cell transplantation after high dose melphalan for multiple myeloma. Twentieth European Bone Marrow Transplant Group Annual Meeting, Harrogate, United Kingdom, March 13-17, 1994 (abstr 318)
41. Heil G, Chadid L, Hoelzer D, et al.: GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia. Leukemia 9:3, 1995
42. Stone RM, Berg DT, George SL, et al.: Granulocyte-macrophage colony-stimulating-factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 332:1671-1677, 1995
43. Calderwood S, Romeyer F, Blachette V, et al.: Concurrent rhGM-CSF does not offset myelosuppression from intensive chemotherapy: Randomized placebo-controlled study in childhood acute lymphoblastic leukemia. Am J Hematol 47:27-32, 1994
44. Prince HM, Imrie K, Sutherland DR, et al.: Peripheral blood progenitor cell collections in multiple myeloma: Predictors and management of inadequate collections. Br J Haematol 93:142-145, 1996
45. Laporte JP, Fouillard L, Douay L, et al.: GM-CSF instead of autologous bone-marrow transplantation after the BEAM regimen. Lancet 338:601-602, 1991